World Allergy Organization Journal (Nov 2021)
Expert consensus on the use of omalizumab in chronic urticaria in China
- Zuotao Zhao, MD, PhD,
- Tao Cai, MD,
- Hong Chen, MD,
- Liuqing Chen, MD,
- Yudi Chen, MD,
- Xiang Gao, MD,
- Xinghua Gao, MD,
- Songmei Geng, MD,
- Yinshi Guo, MD,
- Fei Hao, MD,
- Guodong Hao, MM,
- Yan Hu, MD,
- Hongzhong Jin, MD,
- Zhehu Jin, MD,
- Chengxin Li, MD,
- Haili Li, MD,
- Jie Li, MD,
- Yanming Li, MD,
- Yunsheng Liang, MD,
- Guanghui Liu, MD,
- Qiang Liu, MD,
- Hai Long, MD,
- Lin Ma, MD,
- Yuanyuan Shang, MM,
- Yuxin Song, MB,
- Zhiqiang Song, MD,
- Xiangyang Su, MD,
- Haijing Sui, MD,
- Qing Sun, MD,
- Yuemei Sun, MB,
- Jianping Tang, MD,
- Xunliang Tong, MD,
- Huiying Wang, MD,
- Gang Wang, MD,
- Lianglu Wang, MD,
- Siqin Wang, MB,
- Li Xiang, MD,
- Ting Xiao, MD,
- Zhiqiang Xie, MD.,
- Leping Ye, MD,
- Yongmei Yu, MM,
- Chunlei Zhang, MD, PhD,
- Litao Zhang, MD,
- Shuchen Zhang, MD, PhD,
- Rui Zheng, MD,
- Lili Zhi, MM,
- Wei Zhou, MD,
- Ying Zou, MD,
- Marcus Maurer, MD
Affiliations
- Zuotao Zhao, MD, PhD
- Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China; National Clinical Research Center for Skin and Immune Diseases, Beijing, China; Corresponding author. Department of Dermatology and Venereology, Peking University First Hospital, Xishiku Avenue No. 8, Beijing, PR China.
- Tao Cai, MD
- Department of Dermatology and Venerology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
- Hong Chen, MD
- Department of Dermatology and Venerology, Tianjin People's Hospital, Tianjin Union Medical Center, Tianjin, China
- Liuqing Chen, MD
- Department of Dermatology and Venerology, Wuhan No.1 Hospital, Wuhan, China
- Yudi Chen, MD
- Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
- Xiang Gao, MD
- Department of Allergy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
- Xinghua Gao, MD
- Department of Dermatology and Venerology, The First Hospital of China Medical University, Shenyang, China
- Songmei Geng, MD
- Department of Dermatology and Venerology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Yinshi Guo, MD
- Department of Allergy, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China
- Fei Hao, MD
- Department of Dermatology and Venerology, The Third Affiliated Hospital of Chongqing Medicine University, Chongqing, China
- Guodong Hao, MM
- Department of Allergy, Tangshan Gongren Hospital, Tangshan, China
- Yan Hu, MD
- Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, China
- Hongzhong Jin, MD
- Department of Dermatology and Venerology, Peking Union Medical College Hospital, Chinese Academy Medical Science, Peking Union Medical College, Beijing, China
- Zhehu Jin, MD
- Department of Dermatology and Venerology, Yanbian University Hospital (Yanbian Hospital), Jilin, China
- Chengxin Li, MD
- Department of Dermatology and Venerology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
- Haili Li, MD
- Department of Ophthalmology, Peking University First Hospital, Beijing, China
- Jie Li, MD
- Department of Dermatology and Venerology, Xiangya Hospital Central South University, Changsha, China
- Yanming Li, MD
- Department of Respiratory and Critical Care Medicine, Bejing Hospital, Beijing, China
- Yunsheng Liang, MD
- Department of Dermatology and Venerology, Dermatology Hospital of Southern Medical University, Guangdong Provincial Dermatology Hospital, Guangdong, China
- Guanghui Liu, MD
- Department of Allergy, ZhongNan Hospital of Wuhan University, Wuhan, China
- Qiang Liu, MD
- Department of Dermatology and Venerology, The Second Hospital of Hebei Medical University, Shijiazhuang, China
- Hai Long, MD
- Department of Dermatology and Venerology, The Second Xiangya Hospital of Central South University, Changsha, China
- Lin Ma, MD
- Department of Dermatology and Venerology, Beijing Children's Hospital Capital Medical University, Beijing, China
- Yuanyuan Shang, MM
- Department of Dermatology and Venerology, General Hospital of Ningxia Medical University, Yinchuan, China
- Yuxin Song, MB
- Department of Allergy, Harbin Children's Hospital, Harbin, China
- Zhiqiang Song, MD
- Department of Dermatology and Venerology, The First Affiliated Hospital of Third Military Medical University, Chongqing, China
- Xiangyang Su, MD
- Department of Dermatology and Venerology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
- Haijing Sui, MD
- Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, China
- Qing Sun, MD
- Department of Dermatology and Venerology, Qilu Hospital, Shandong University, Jinan, China
- Yuemei Sun, MB
- Department of Allergy, Yantai Yuhuangding Hospital, Yantai, China
- Jianping Tang, MD
- Department of Dermatology and Venerology, Hunan Children's Hospital, Changsha, China
- Xunliang Tong, MD
- Department of Respiratory and Critical Care Medicine, Bejing Hospital, Beijing, China
- Huiying Wang, MD
- Department of Allergy, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
- Gang Wang, MD
- Department of Dermatology and Venerology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
- Lianglu Wang, MD
- Department of Allergy, Peking Union Medical College Hospital, Beijing, China
- Siqin Wang, MB
- Department of Allergy, Henan Provincial Peoples Hospital, Zhengzhou, China
- Li Xiang, MD
- Department of Allergy, Beijing Children's Hospital Capital Medical University, Beijing, China
- Ting Xiao, MD
- Department of Dermatology and Venerology, The First Hospital of China Medical University, Shenyang, China
- Zhiqiang Xie, MD.
- Department of Dermatology and Venerology, Peking University Third Hospital, Beijing, China
- Leping Ye, MD
- Department of Paediatrics, Peking University First Hospital, Beijing, China
- Yongmei Yu, MM
- Department of Otorhinolaryngology Head and Neck Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, China
- Chunlei Zhang, MD, PhD
- Department of Dermatology and Venerology, Peking University Third Hospital, Beijing, China
- Litao Zhang, MD
- Department of Dermatology and Venerology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China
- Shuchen Zhang, MD, PhD
- Department of Allergy, Tongji Medical College, Huazhong University of Science&Technology, Wuhan, China
- Rui Zheng, MD
- Department of Dermatology and Venerology, The First Hospital of Shanxi Medical University, Taiyuan, China
- Lili Zhi, MM
- Department of Allergy, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Shandong Institute of Respiratory Diseases, Jinan, China
- Wei Zhou, MD
- Department of Paediatrics, Peking University Third Hospital, Beijing, China
- Ying Zou, MD
- Department of Dermatology and Venerology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
- Marcus Maurer, MD
- Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany; Corresponding author. Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117, Berlin, Germany.
- Journal volume & issue
-
Vol. 14,
no. 11
p. 100610
Abstract
Chronic urticaria (CU) is a debilitating skin disease that lasts for more than 6 weeks with wheals and/or angioedema, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). In China, the prevalence of this disease is high, more than 1%, and on the rise. CU has a major impact on the quality of life (QoL) of patients who frequently experience sleep disturbance, depression, and anxiety. Nearly one-third of patients with CSU, in China, are resistant to second-generation H1-antihistamines (sgAHs), even at a fourfold dose (second line; off-label). Omalizumab is approved for the treatment of CSU treatment in Europe and shows remarkable efficacy and safety. In China, regulatory approval for the use of omalizumab is pending, and its use in clinical practice varies widely. Consensus on omalizumab CU treatment in China is urgently needed. The aim of this article is to propose a practical omalizumab treatment algorithm for the management of antihistamine-resistant CSU and CIndU in adults and special population including children and adolescents, and pregnant or breast feeding women, to guide daily clinical practice in China. In the development of this consensus, an expert group including mainly dermatologists, allergists, but also pulmonologists, ENTs, immunologists, and pediatricians in Allergic Disease Prevention and Control Committee, Chinese Preventive Medicine Association, reviewed the existing evidence and developed consensus on the use of omalizumab in CU patients from China. The goal of this consensus is to assist clinicians in making rational decisions in the management of refractory CU with omalizumab. The key clinical questions covered by the treatment algorithm are: 1) Omalizumab treatment routine strategy in both CSU and CIndU patients; 2) Recommended dose and treatment duration for different age stratification; 3) Treatment duration for CU patients with other allergic comorbidities; 4) Recommendation on omalizumab stopping strategy.
